Venus Remedies Share Price Gains Nearly 5% After Q1 FY27 Consolidated Profit Surges 139% to Rs 22.97 Crore

Venus Remedies share price up 4.99% at Rs 1,778.50. Q1 FY27 consolidated PAT Rs 22.97 crore, up 139.27% YoY. Revenue Rs 178.86 crore, up 30.38% YoY.

The Venus Remedies share price gained nearly 5 percent on 21 July 2026 after the pharmaceutical company reported a striking Q1 FY27, with consolidated net profit surging 139.27 percent year on year to Rs 22.97 crore on the back of 30.38 percent revenue growth to Rs 178.86 crore, driven by expansion across its manufacturing and export operations.

Click Here – Get Free Investment Predictions

About Venus Remedies

Venus Remedies is a pharmaceutical company focused on injectable formulations, oncology, and critical care products, with a significant presence in both the Indian domestic market and international export markets across multiple continents.

The company has been investing in expanding its manufacturing capacity and research capabilities, particularly in complex injectable and specialty formulations that carry higher margins than standard generic products.

Export markets have become an increasingly important growth driver for Venus Remedies, with the company’s regulatory approvals across multiple geographies supporting the kind of broad based revenue growth reflected in this quarter’s Venus Remedies share price reaction.

Venus Remedies Q1 FY27 Results: Key Numbers

The Venus Remedies share price rally is driven by profit growth of 139.27 percent that significantly outpaced the already strong 30.38 percent revenue growth, indicating meaningful margin expansion within the pharmaceutical manufacturing and export business during the quarter.

The scale of the profit surge, more than doubling year on year, suggests better cost absorption kicking in as manufacturing capacity utilisation improves alongside a favourable product mix shift toward higher margin injectable and specialty formulations.

While profit surged sequentially it remains below the Rs 47.49 crore reported in Q4 FY26, a reminder that pharmaceutical export businesses can see meaningful quarter to quarter variability tied to shipment timing and regulatory approval cycles, a factor investors in the Venus Remedies share price should keep in mind.

Consult a SEBI Registered Investment Advisor on Univest

Why Venus Remedies Share Price Is Reacting

The Venus Remedies share price is reacting strongly because sustained expansion across pharmaceutical manufacturing and export operations, evidenced by 30 percent plus revenue growth, combined with profit more than doubling, signals the company’s investments in capacity and specialty formulations are beginning to pay off meaningfully.

Injectable and critical care formulations typically command better margins and face less commoditised pricing pressure than standard oral generics, and continued growth in this segment appears to be a key driver behind the margin expansion this quarter.

Export market diversification across multiple geographies reduces Venus Remedies’s dependence on any single regulatory or pricing environment, a structural positive that likely contributed to investor enthusiasm behind the Venus Remedies share price move.

Outlook for Venus Remedies Share Price

Investors tracking the Venus Remedies share price should watch for consistency in coming quarters, given the sequential decline from Q4 FY26 levels, to assess whether Q1 FY27’s strong YoY growth represents a sustainable new baseline or was aided by favourable shipment timing.

Continued capacity expansion and new regulatory approvals in key export markets would support the medium term growth case, particularly for the higher margin injectable and specialty formulation segments the company has been prioritising.

Raw material and active pharmaceutical ingredient cost trends will remain a variable to watch, since these directly affect margins in the specialty and generic injectable segments that are central to the Venus Remedies share price growth story.

Download the Univest iOS App or Univest Android App to track Venus Remedies share price live and get instant Q1 result alerts.

Conclusion

Venus Remedies delivered an exceptional Q1 FY27, with consolidated profit surging 139.27 percent to Rs 22.97 crore on 30.38 percent revenue growth, lifting the Venus Remedies share price nearly 5 percent on 21 July 2026. Sustained expansion in injectable and export focused formulations appears to be driving genuine margin improvement, though sequential trends warrant monitoring for consistency. Consult a SEBI registered adviser before acting on the Venus Remedies share price.

FAQs on Venus Remedies Q1 FY27 Results

Why did Venus Remedies share price rise on 21 July 2026?

Ans. The Venus Remedies share price rose nearly 5 percent after the company reported Q1 FY27 consolidated net profit of Rs 22.97 crore, up 139.27 percent year on year, on revenue growth of 30.38 percent to Rs 178.86 crore.

What was Venus Remedies’s revenue growth in Q1 FY27?

Ans. Venus Remedies reported consolidated revenue from operations of Rs 178.86 crore in Q1 FY27, up 30.38 percent from Rs 137.18 crore in Q1 FY26.

What products does Venus Remedies focus on?

Ans. Venus Remedies focuses on injectable formulations, oncology, and critical care pharmaceutical products, with a presence in both the Indian domestic market and international export markets.

Why did profit grow faster than revenue in Q1 FY27?

Ans. Profit growth of 139.27 percent outpaced the 30.38 percent revenue growth, indicating margin expansion likely driven by a favourable shift toward higher margin injectable and specialty formulations.

Is Venus Remedies’ profit growth sustainable quarter to quarter?

Ans. Q1 FY27 profit was below the Rs 47.49 crore reported in Q4 FY26, showing sequential variability tied to shipment timing and regulatory approval cycles common in pharmaceutical export businesses.

Is Venus Remedies share price a buy after the Q1 results?

Ans. This article does not constitute investment advice. While growth was exceptional, investors should assess sequential consistency and consult a SEBI registered adviser before acting on the Venus Remedies share price.

Where can I track Venus Remedies share price live?

Ans. You can track the Venus Remedies share price live on the Univest app and website, along with quarterly result alerts and research on pharmaceutical and healthcare stocks.